Ticagrelor approved for use in NHS Scotland

Clot-busting drug ticagrelor will be available for patients in NHS Scotland after a review by the Scottish Medicines Consortium (SMC).

Clinicians can prescribe the anti-platelet treatment, co-administered with aspirin, for the prevention of atherothrombotic events in adults with acute coronary syndromes including prior MI, the SMC ruled.

Results from the PLATO trial showed ticagrelor plus aspirin showed a reduction in ischaemic events compared with standard treatment.

Patients who took the drug had 21% reduced relative risk of cardiovascular death and 16% lower relative risk of repeat cardiovascular events compared with standard care, with no increase in major bleeding.

NICE is currently reviewing evidence for the treatment and is set to publish full guidance later this year.


Have you registered with us yet?

Register now to enjoy more articles and free email bulletins


Already registered?

Sign in

Just published

BMA sign

GPs reject 'insulting' contract as BMA issues stark warning over 'death of general practice'

GP leaders have rejected 'insulting' proposed changes to the GP contract for 2023/23,...

Talking General Practice logo

Podcast: Why underdoctored areas face a vicious cycle and how NHS plans could hit GP workload

The team discusses our new GP Insight tool and what it tells us about the GP workforce...

GP consultation

GP partners in decline in almost every part of England

GP partners are in decline in almost every part of England - with the proportion...

GP sign

Half of GPs have cut working hours to ease workload, poll shows

More than half of GPs have reduced their working hours because of intense workload...

Dr Ifthikar Lone

'Doctor Boro': GP who survived COVID-19 inspires folk song

A Middlesbrough GP who survived a severe COVID-19 infection early in the pandemic...

Patients in GP waiting room

Where in England are patients per GP rising fastest?

GPs are responsible for up to 13% more patients now than they were just two years...